Clinical Trials Logo

Filter by:
NCT ID: NCT03115112 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Start date: October 12, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

NCT ID: NCT03112603 Completed - Clinical trials for Graft-versus-host Disease (GVHD)

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Start date: June 29, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

NCT ID: NCT03110016 Completed - Clinical trials for Subthreshold Depression

Smartphone Intervention for Subthreshold Depression

Start date: May 16, 2017
Phase: N/A
Study type: Interventional

The study aimed to examine the feasibility, usability, user satisfaction, safety, and preliminary efficacy of a smartphone application intervention for young adults with subthreshold depression.

NCT ID: NCT03106623 Completed - Overactive Bladder Clinical Trials

Study of ONO-8577 in Patients With Overactive Bladder

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder

NCT ID: NCT03105128 Completed - Crohn's Disease Clinical Trials

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Start date: May 10, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).

NCT ID: NCT03101267 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

A Dose-finding Study of ASP4070

Start date: April 13, 2017
Phase: Phase 2
Study type: Interventional

The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.

NCT ID: NCT03100825 Completed - Asthma Clinical Trials

A Long-term Safety Study of QVM149 in Japanese Patients With Asthma

Start date: April 28, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide long term safety data of QVM149 in Japanese patients with asthma for the registration of QVM149 in Japan.

NCT ID: NCT03100500 Completed - Asthma Clinical Trials

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

Start date: April 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.

NCT ID: NCT03100318 Completed - Clinical trials for Hyperuricemia With or Without Gout

Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: April 1, 2017
Phase: Phase 3
Study type: Interventional

FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.

NCT ID: NCT03099174 Completed - Neoplasms Clinical Trials

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Start date: May 4, 2017
Phase: Phase 1
Study type: Interventional

This is a study in adult patients with different types of cancer. The purpose of this study is to find a safe dose of: - Xentuzumab in combination with abemaciclib - Xentuzumab in combination with abemaciclib and hormonal therapies The study also tests whether these medicines make tumours shrink in participants with lung and breast cancer. Participants can stay in the study as long as they benefit from and can tolerate treatment. All participants get xentuzumab infusions and abemaciclib tablets. Participants who have breast cancer get different types of hormonal therapies in addition to xentuzumab and abemaciclib. For all participants, the size of the tumour is measured regularly. Doctors also regularly check the general health of the participants."